Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 12/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23559023 | 1.00 | MET (0.45) | METHDAC1KDM4EGRIN1GRIN2B | |
| SCHEMBL26529054 | 0.92 | MET (0.46) | METHDAC1KDM4EPDE4APDE4B | |
| SCHEMBL23297285 | 0.89 | PDE4A (0.51) | METHDAC1PDE4APDE4BPDE4C | |
| SCHEMBL29569742 | 0.85 | MEN1 (0.41) | METGRIN1GRIN2BPDE4APDE4B | |
| SCHEMBL23558978 | 0.85 | MEN1 (0.41) | METGRIN1GRIN2BPDE4APDE4B | |
| SCHEMBL23297321 | 0.85 | MET (0.52) | MET | |
| SCHEMBL29776791 | 0.85 | MET (0.52) | MET | |
| SCHEMBL23528794 | 0.84 | GRIN1 (0.42) | METHDAC1GRIN1GRIN2BPDE4A | |
| Sevasemten SCHEMBL23528413 | 0.84 | MET (0.42) | METGRIN1GRIN2B | |
| SCHEMBL26999039 | 0.84 | MET (0.46) | METHDAC1PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223278-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2025-07-10 | — | — | US | disclosed |
| US-12240831-B2 | Pyridazinone compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| US-12012395-B2 | Pyridazinone compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| US-20240025879-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| EP-4248973-A2 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20220106291-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2022-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12012395-B2 | Pyridazinone compounds and uses thereof | IL6, IL1B, IL1A | MET 4212/4885HDAC1 333/4885KDM4E 3514/4885 |
| US-12240831-B2 | Pyridazinone compounds and uses thereof | IL6, IL1B, IL1A | MET 4212/4885HDAC1 333/4885KDM4E 3514/4885 |
| US-20220106291-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | MET 4212/4885HDAC1 333/4885KDM4E 3514/4885 |
| US-20250223278-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | MET 4212/4885HDAC1 333/4885KDM4E 3514/4885 |
| US-20240025879-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | MET 4212/4885HDAC1 333/4885KDM4E 3514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.